Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Six Patent Applications Related to RNAi: Oct 26, 2006

Premium
Title: Metabolically Activated Recombinant Viral Vectors and Methods for Their Preparation and Use
 
Number: 7,125,717
 
Filed: April 25, 2003
 
Inventor: Barrie Carter, Targeted Genetics
 
According to the patent’s abstract, the invention covers “recombinant viral vectors, especially parvovirus vectors such as adeno-associated virus vectors, capable of enhanced expression of heterologous sequences, and methods for their construction and use. The vectors have a structure, or are capable of rapidly adopting a structure, which involves intrastrand base pairing of at least one region in a heterologous sequence.”
 

 
Title: Cloning and Characterization of microRNAs from Rice         
 
Number: 20060236429
 
Filed: March 29, 2006
 
Lead Inventor: Jian-Kang Zhu, University of California, Riverside
 
The invention, the patent application’s abstract states, “provides new miRNAs in rice. The nucleic acids of the invention can be used to control gene expression in plants.”
 

 
Title: MicroRNAs for Plant Growth and Development         
 
Number: 20060236427
 
Filed: Sept. 20, 2005
 
Lead Inventor: Vincent Lee Chuan Chiang, North Carolina State University
 
The patent application, its abstract states, “provides methods and compositions for modulating gene expression in plants. Also provided are plants and cells comprising the compositions of the presently disclosed subject matter.”
 

 
Title: Transcription Factor RNA Interference and Methods of Use Thereof         
 
Number: 20060234973
 
Filed: April 12, 2006
 
Lead Inventor: Kevin Fitzgerald, Bristol-Myers Squibb
 
According to the patent application’s abstract, the invention “concerns methods and reagents useful in modulating transcription factor gene expression in a variety of applications, including methods of use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules … capable of mediating RNA interference against E2F1 gene expression, useful in the treatment of cell cycle disorders, inflammatory conditions, reproductive disorders, cancers, and any other condition that responds to modulation of E2F1 expression and/or activity.”
 

 
Title: Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure         
 
Number: 20060234970
 
Filed: Feb. 22, 2006
 
Lead Inventor: Ana Jimenez
 
The invention relates to “methods and compositions that decrease intraocular pressure of the eye,” the patent application’s abstract states. “The compositions of the invention comprise short interfering nucleic acid molecules … that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention,” the abstract adds.
 

 
Title: Method for Expressing Inducible RNAi in Cells, Nucleic Acid Molecules Therefore, and Cells Transformed by Said Molecules         
 
Number: 20060234966
 
Filed: Nov. 21, 2003 PCT Filed: Nov. 21, 2003
 
Lead Inventor: Harel-Bellan Annick, French National Center for Scientific Research
 
According to the patent application’s abstract, the invention comprises “a method of expressing RNAi in cells. [This method includes] introducing into cells a molecule of nucleic acid including the sequence sense and antisense of RNAi placed under the control of a promoter of single transcription, which sense and antisense sequences are separated by a sequence of DNA including a sequence for the stop of this transcription, which DNA sequence is framed at each of its ends by a lox site, and placing Cre in contact of the lox sites to obtain by site-specific recombination the elimination of the DNA sequence and the stop sequence of the transcription such that the sense and antisense sequences are no longer separated except by the remaining lox sequence and, thus, permit transcription of the RNAi in its entirety with the residual lox sequence as a loop.”
 

 
Title: Process for Reducing the Acrylamide Content of Heat-Treated Foods
 
Number: 20060233930
 
Filed: Nov. 7, 2003 PCT Filed: Nov. 7, 2003
 
Lead Inventor: Stephan Soyka, Bayer Cropscience
 
The invention “relates to a process for reducing the acrylamide content of heat-treated foods compared with corresponding conventional heat-treated foods,” the patent application’s abstract states.
 
The application notes that this process involves reducing “the activity of one or more endogenous R1 proteins occurring in the plant cell” using “foreign nucleic acid molecules” such as double-stranded RNA.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.